메뉴 건너뛰기
Neurology
Volumn 79, Issue 6, 2012, Pages 498-499
The elusive biomarker for personalized medicine in multiple sclerosis: The search continues
Author keywords

[No Author keywords available]
Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; BIOLOGICAL MARKER; INTERFERON BETA SERINE; INTERLEUKIN 17; INTERLEUKIN 17F; PLACEBO;
EID: 84866053932     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318259e13a     Document Type: Editorial
Times cited : (7)
References (10)
  • 1
    • 0038290597 scopus 로고    scopus 로고
    • Interferons in relapsing remitting multiple sclerosis
    • Cohen JA, Rudick RA, eds., 2nd ed. London: Martin Dunitz;
    • Kappos L. Interferons in relapsing remitting multiple sclerosis. In: Cohen JA, Rudick RA, eds. Multiple Sclerosis Therapeutics, 2nd ed. London: Martin Dunitz; 2003.
    • (2003) Multiple Sclerosis Therapeutics
    • Kappos, L.1
  • 2
    • 29144495498 scopus 로고    scopus 로고
    • The distribution of magnetic resonance imaging response to interferonbeta-1b in multiple sclerosis
    • Sormani MP, Bruzzi P, Beckmann K, et al. The distribution of magnetic resonance imaging response to interferonbeta-1b in multiple sclerosis. J Neurol 2005;252: 1455-1458.
    • (2005) J Neurol , vol.252 , pp. 1455-1458
    • Sormani, M.P.1    Bruzzi, P.2    Beckmann, K.3
  • 3
    • 4844223606 scopus 로고    scopus 로고
    • Defining interferon beta response status in multiple sclerosis patients
    • Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 2004;56:548 -555.
    • (2004) Ann Neurol , vol.56 , pp. 548-555
    • Rudick, R.A.1    Lee, J.C.2    Simon, J.3    Ransohoff, R.M.4    Fisher, E.5
  • 4
    • 46749147136 scopus 로고    scopus 로고
    • Relationship between MRI lesion activity and response to IFN-beta in relapsingremitting multiple sclerosis patients
    • Rio J, Rovira A, Tintore M, et al. Relationship between MRI lesion activity and response to IFN-beta in relapsingremitting multiple sclerosis patients. Mult Scler 2008;14: 479-484.
    • (2008) Mult Scler , vol.14 , pp. 479-484
    • Rio, J.1    Rovira, A.2    Tintore, M.3
  • 5
    • 44449105085 scopus 로고    scopus 로고
    • MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosis
    • Durelli L, Barbero P, Bergui M, et al. MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosis. J Neurol Neurosurg Psychiatry 2008;79:646-651.
    • (2008) J Neurol Neurosurg Psychiatry , vol.79 , pp. 646-651
    • Durelli, L.1    Barbero, P.2    Bergui, M.3
  • 6
    • 70350135509 scopus 로고    scopus 로고
    • One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis
    • Prosperini L, Gallo V, Petsas N, Borriello G, Pozzilli C. One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis. Eur J Neurol 2009;16:1202-1209.
    • (2009) Eur J Neurol , vol.16 , pp. 1202-1209
    • Prosperini, L.1    Gallo, V.2    Petsas, N.3    Borriello, G.4    Pozzilli, C.5
  • 7
    • 77950534540 scopus 로고    scopus 로고
    • T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis
    • Axtell RC, de Jong BA, Boniface K, et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 2010;16:406-412.
    • (2010) Nat Med , vol.16 , pp. 406-412
    • Axtell, R.C.1    De Jong, B.A.2    Boniface, K.3
  • 8
    • 84862741487 scopus 로고    scopus 로고
    • Serum IL-17F does not predict poor response to im IFNβ-1a in relapsing-remitting MS
    • Bushnell SE, Zhao Z, Stebbins CC, et al. Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS. Neurology 2012;79:531-537.
    • (2012) Neurology , vol.79 , pp. 531-537
    • Bushnell, S.E.1    Zhao, Z.2    Stebbins, C.C.3
  • 9
    • 0037180468 scopus 로고    scopus 로고
    • A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS
    • Clanet M, Radue EW, Kappos L, et al. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 2002;59:1507-1517.
    • (2002) Neurology , vol.59 , pp. 1507-1517
    • Clanet, M.1    Radue, E.W.2    Kappos, L.3
  • 10
    • 84858147904 scopus 로고    scopus 로고
    • Risk stratification and patient counseling for natalizumab in multiple sclerosis
    • Fox RJ, Rudick RA. Risk stratification and patient counseling for natalizumab in multiple sclerosis. Neurology 2012;78:436-437.
    • (2012) Neurology , vol.78 , pp. 436-437
    • Fox, R.J.1    Rudick, R.A.2

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.